Trader's Buzzers Protalix Biotherapeutics Inc (NYSEMKT:PLX), Chimera Investment Corporation (NYSE:CIM)

Mar 17, 2017, 01:19

The Average Volume of the company is 3.9 Million and P/E (price to earnings) ratio is 3.1, while Forward P/E ratio is 0. The Low Price target projection by analysts is $1.2 and the Mean Price Target is $2.6. (PLX) was up +21.19% during the last trading session, with a day high of 1.48.

Protalix Biotherapeutics Inc (NYSEMKT:PLX) will issue its quarterly earnings data on Thursday, March 16th. The stock's 52-week range is $0.26 - $1.51.

Many Analysts provided their foresight on Revenue Estimates of Protalix BioTherapeutics, Inc. where they believe that the company has the potential to earn average revenue of $1.2 Million for the current quarter. The stock is now has its Return on Assets (ROA) value of -2.2 Percent. While some analysts have a High Price target for the stock of $4 and a Low Price Target of $1.2.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) topped its 52-week high price of $1.48 on Mar 13, 2017 and 52-Week Low Price of $0.26 on Dec 13, 2016. They now have a United States dollars 3.4 price target on the stock. The firm has a market cap of $143.74 million, a price-to-earnings ratio of 3.10 and a beta of 0.95. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. JP Morgan Maintains the company's stock to Overweight on 5/13/14 by setting a price target of $7. While the actual EPS the company reported in the same quarter previous year was 0.77/share. In Protalix Biotherapeutics Inc (NYSEMKT:PLX)'s last 12 earnings reports, it has beaten EPS estimates 41% of the time. Full-year profit views are for Protalix BioTherapeutics, earn -$0.38 in current year and grow profits by almost -162.3% over last year's earnings of $0.61.

11/12/2014 - Protalix BioTherapeutics, Inc. had its "buy" rating reiterated by analysts at R. F. Lafferty.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) has a market capitalization of 203.9 Million.

The stock's price switched up 30.47% 20-Days Simple Moving Average, added 85.86% from 50-Days Simple Moving Average and rose 129.11% from 200 Days Simple Moving Average.

Protalix BioTherapeutics, Inc. (NYSE:PLX) yearly performance is 57.14%. There was a stock increase by 0.7 percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) of 0 percent.

The High Revenue estimate is predicted as 1.5 Million, while the Low Revenue Estimate prediction stands at 900 Million. As the past trend shows, Protalix BioTherapeutics, Inc.'s stock price has plunged after earnings in 3 of the last 4 quarters.